Furthermore, the induction of the MDM2-p53 autoregulatory loop by frontline cytotoxic agents provides fertile ground to develop novel anti-cancer targeted therapies that sustain p53 activation and increase cancer-cell sensitivity to lower doses of cytotoxic therapy. This evidence concerns the gene TP53 and cancer.